In this study, SIN modulation of TGF-β1 targeted regulation of NF-κB and PI3K/AKT pathways to achieve remission of pulmonary fibrosis, which is promising to provide ideas for the in vivo typing-targeted treatment of IPF, as well as contributing to the precision medicine treatment of IPF. The gene discussed is AKT1; the disease is idiopathic pulmonary fibrosis.